Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised Double Blind, Multiple Dose, Pharmacokinetic and Safety Study of SENS 401 in Healthy Subjects

Next Previous
Trial Profile

A Randomised Double Blind, Multiple Dose, Pharmacokinetic and Safety Study of SENS 401 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arazasetron (Primary)
  • Indications Hearing loss; Sensorineural hearing loss
  • Focus Adverse reactions

Most Recent Events

  • 29 Jun 2018 According to a Sensorion media release, data from this trial were presented at the 15th International Conference on Cochlear Implants and Other Implantable Auditory Technologies (Ci2018).
  • 14 Feb 2018 According to a Sensorion media release, results were presented at the Association for Research in Otolaryngologys (ARO) 41st Annual MidWinter Meeting.
  • 18 Oct 2017 Status changed from active, no longer recruiting to completed, according to a Sensorion media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top